(Note: This is NOT an IPO. This is a NASDAQ uplisting from Euronext Paris. This is a public offering of American Depositary Shares in the U.S. and a private placement of ordinary shares in France and elsewhere in Europe.)

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (“UC”). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease (“CD”), as well as evaluating other potential inflammatory indications.

We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases (“IBD”), chronic conditions involving inflammation of the gastrointestinal (“GI”) tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of approximately 2.9 million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and Japan suffered from IBD, with 1.5 million of these patients in the United States alone.

*Note: Revenue (operating income) and net losses are for the 12 months that ended June 30, 2023.

(Abivax S.A. priced its global offering in connection with its NASDAQ uplisting/ADS public offering and a concurrent European private placement of ordinary shares on Oct. 19, 2023, in sync with the terms in its revised prospectus: 20.33 million new ordinary shares were priced in the global offering with the breakdown as follows: 18.7 million American Depositary Shares at $11.60 – the low end of the U.S. public offering’s $11.60-to-$13.00 per ADS price range – to raise $216.91 million in the U.S. offering – and a concurrent offering of 1,626,040 ordinary shares in the European private placement to certain European investors at a corresponding offering price of 10.98 euros (€10.9864) per ordinary share based on an exchange rate of €1.00 = $1.0559 as published by the European Central Bank on October 19, 2023. The American Depositary Shares are expected to start trading today (Friday, Oct. 20, 2023) on the NASDAQ.)

(Abivax S.A. increased the size of its global offering to 20.33 million shares – up from 18.68 million shares originally – in an F-1/A filing dated Oct. 18, 2023. The offering’s estimated proceeds remain at $250.06 million. The price range will be $11.60 to $13.00 per American Depositary Share (ADS), based on the ordinary share’s closing price on Wednesday, Oct. 18, 2023, of US$12.51 (the as-converted price of its close at 11.84 euros) on the Euronext Paris. The price range for the ordinary shares offered in the private placement in Europe will be between 10.98 eueros and 12.30 euros per ordinary share, according to the F-1/A filing dated Oct. 18, 2023. The offering’s initial terms – disclosed Oct. 16, 2023, in an F-1/Aa filing – cited the stock’s closing price on the Euronext Paris on Oct. 13, 2023, of 12.72 euros, equivalent to US$13.39.)